Nebivolol 5mg + Amlodipine 5mg Tablet in PCD Pharma Franchise in Delhi

Nebivolol 5mg + Amlodipine 5mg Tablet in Pharmaceutical Manufacturing Company in Baddi

Nebivolol 5mg + Amlodipine 5mg Tablet in Cardiac Care Pharma Franchise in Mumbai

Nebivolol 5mg + Amlodipine 5mg Tablet in Pharma Distributors & Suppliers in Hyderabad

Nebivolol 5mg + Amlodipine 5mg Tablet in Pharma Export Company in Chennai
Nebivolol 5mg + Amlodipine 5mg Tablet in Pharma Franchise Opportunity in Bengaluru

Home/Products /nebivolol-5-mg-amlodipine-5-mg-tablet

Nebiroll A Tablet

Composition : Nebivolol 5 mg + Amlodipine 5 mg Tablet

Dosage Form : Tablet

Packaging Type : Alu Alu

Packaging : 10*10

Price : ₹1/-

This combination tablet contains Nebivolol, a highly selective beta-1 adrenergic blocker with nitric oxide–mediated vasodilatory effects, and Amlodipine, a long-acting calcium channel blocker (CCB) of the dihydropyridine class. Nebivolol works by reducing heart rate and myocardial oxygen demand while improving arterial compliance and endothelial function. Amlodipine relaxes vascular smooth muscles by inhibiting calcium influx into cells, leading to potent arterial vasodilation and reduced peripheral vascular resistance. Together, they provide complementary mechanisms for controlling blood pressure: Nebivolol addresses cardiac output and heart rate control, while Amlodipine targets arterial vasodilation. This dual action offers enhanced blood pressure reduction, reduced cardiovascular risk, and improved patient compliance by combining two antihypertensives in a single daily dose. It is particularly useful in patients requiring combination therapy due to uncontrolled hypertension with monotherapy.

Read More

About the Product

This combination tablet contains Nebivolol, a highly selective beta-1 adrenergic blocker with nitric oxide–mediated vasodilatory effects, and Amlodipine, a long-acting calcium channel blocker (CCB) of the dihydropyridine class. Nebivolol works by reducing heart rate and myocardial oxygen demand while improving arterial compliance and endothelial function. Amlodipine relaxes vascular smooth muscles by inhibiting calcium influx into cells, leading to potent arterial vasodilation and reduced peripheral vascular resistance. Together, they provide complementary mechanisms for controlling blood pressure: Nebivolol addresses cardiac output and heart rate control, while Amlodipine targets arterial vasodilation. This dual action offers enhanced blood pressure reduction, reduced cardiovascular risk, and improved patient compliance by combining two antihypertensives in a single daily dose. It is particularly useful in patients requiring combination therapy due to uncontrolled hypertension with monotherapy.

Common side effects include headache, dizziness, flushing, ankle swelling (edema), fatigue, and mild gastrointestinal disturbances. Nebivolol may cause bradycardia (slow heart rate), while Amlodipine is associated with peripheral edema due to vasodilation. Rare but serious adverse effects include severe hypotension, worsening of heart failure, allergic reactions, and atrioventricular block. Most side effects are mild and dose-dependent.

Nebivolol 5 mg + Amlodipine 5 mg Tablet is indicated for the management of essential hypertension in adults who require combination therapy to achieve optimal blood pressure control. It is especially beneficial in patients with coexisting conditions such as ischemic heart disease, stable angina, or left ventricular hypertrophy.

This combination should be used only under strict medical supervision. It is contraindicated in patients with severe bradycardia, advanced heart block, cardiogenic shock, or severe heart failure unless recommended by a specialist. Caution is advised in patients with liver or kidney impairment, hypotension, or peripheral edema. The combination is not recommended during pregnancy and breastfeeding unless the potential benefits outweigh the risks. Abrupt discontinuation should be avoided, as sudden withdrawal may lead to rebound hypertension or worsening of cardiac symptoms. Alcohol intake should be minimized as it can potentiate the hypotensive effect. Regular monitoring of blood pressure, heart rate, and clinical status is recommended during long-term therapy.

Store the tablets in a cool, dry place below 30°C, protected from direct sunlight and moisture. Keep the medication in its original blister packaging and out of reach of children. Do not use beyond the expiry date mentioned on the pack.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Strategic Advisory

Ms. Shiwani Dhiman

VP-Strategic Outreach & Engagement

Ms. Shiwani specializes in market outreach and strategic partnership orchestration for entrepreneurs building scalable PCD Pharma Franchise models.

View Professional Profile

Start Your Journey

Partner With Cafoli

Ready to Dominate your territory with a Monopoly-Based PCD Franchise? Join our rapidly growing network of successful franchise partners and turn your ambitions into reality. Limited Territories Available — Don’t Miss Out!

Quick Navigation